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All living cells release extracellular vesicles having pleiotropic 
functions in intercellular communication. Mammalian extra-
cellular vesicles, also known as exosomes and microvesicles, 
are spherical bilayered proteolipids composed of various 
bioactive molecules, including RNAs, DNAs, proteins, and 
lipids. Extracellular vesicles directly and indirectly control a 
diverse range of biological processes by transferring membrane 
proteins, signaling molecules, mRNAs, and miRNAs, and 
activating receptors of recipient cells. The active interaction of 
extracellular vesicles with other cells regulates various 
physiological and pathological conditions, including cancer, 
infectious diseases, and neurodegenerative disorders. Recent 
developments in high-throughput proteomics, transcriptomics, 
and lipidomics tools have provided ample data on the common 
and specific components of various types of extracellular 
vesicles. These studies may contribute to the understanding of 
the molecular mechanism involved in vesicular cargo sorting 
and the biogenesis of extracellular vesicles, and, further, to the 
identification of disease-specific biomarkers. This review 
focuses on the components, functions, and therapeutic and 
diagnostic potential of extracellular vesicles under various 
pathophysiological conditions. [BMB Reports 2014; 47(10): 
531-539]
INTRODUCTION
Intercommunication among cells is crucial in all living 
organisms. Such cell-to-cell communication is achieved 
through direct interactions or via secretion of soluble factors 
(1, 2). Recently, extracellular vesicles (EVs) have gained atten-
tion as mediators of cellular communications. The release of 
EVs is an evolutionarily conserved process, from archaea, 
Gram-negative and Gram-positive bacteria, to eukaryotic cells 
(3, 4). EVs are lipid bilayer-enclosed vesicles, 30-2,000 nm in 
diameter (1-4). These EVs harbor various proteins, lipids, and 
nucleic acids, influencing neighboring and distant cells (1-4). 
EVs are classified based on their biogenesis or cellular origin 
and biological function (5, 6). Specifically, EVs are categorized 
into ectosomes (neutrophils or monocytes), microparticles 
(platelets or endothelial cells), tolerosomes (serum of anti-
gen-fed mice), prostatosomes (seminal fluid), cardiosomes 
(cardiomyocytes), and vexosomes (adeno-associated virus vec-
tors) (5, 7). On the basis of biogenesis, EVs are further catego-
rized into exosomes and microvesicles (1, 2) (Fig. 1). 
However, exosomes and microvesicles, having similar proper-
ties, are difficult to separate despite various efforts to character-
ize and isolate by density, size, morphology, and protein and 
lipid composition (6, 8).
　Exosomes are budded out from the fusion of plasma mem-
branes with the multivesicular bodies (MVBs), the large endo-
somal structures with multiple vesicles in the cytosol (6). The re-
leased exosomes are homogenous vesicles, of around 40-100 nm 
in diameter, with a density of 1.13-1.19 g/ml (9). Exosomes con-
tain endosomal proteins such as tetraspanins (CD9, CD63), Alix, 
and TSG101, which are used as exosomal markers (9, 10). Unlike 
exosomes, microvesicles, also known as ectosomes, shedding 
vesicles, microparticles, and plasma membrane-derived vesicles, 
originate from the plasma membrane by outward budding and fis-
sion (11). Microvesicles are about 50-1,000 nm in diameter, but 
their density is undefined (7, 11). The major differences between 
exosomes and microvesicles arise from differences in their 
composition. Microvesicles are generated by budding from the 
plasma membrane and thus resemble the plasma membrane com-
position of the parent cell. On the other hand, exosomes gen-
erated by inward budding and fission with MVBs, are composed 
of various cytosolic proteins related to endolysosomal pathways. 
Although exosomes and microvesicles contain specific markers, 
these markers are not sufficiently specific to distinguish among 
them.
COMPONENTS OF EXTRACELLULAR VESICLES
Proteins
Extensive investigations of extracellular vesicular proteins have 
been carried out using mass spectrometry (MS)-based proteo-
mic analyses, Western blotting, and immune-electron micro-
scopy (12, 13). MS-based proteomic studies of EVs have pro-
vided a high-throughput vesicular proteome dataset in various 
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Fig. 1. Intercellular communication via extracellular vesicles. EVs are lipid-bilayered vesicles of 30-2,000 nm in diameter. Mammalian EVs 
are classified into exosomes and microvesicles, based on their biogenesis. Exosomes and microvesicles are generated by the fusion of 
multivesicular bodies with the plasma membrane and budding from the plasma membrane, respectively. EVs are intercellular communica-
somes, harboring diverse bioactive materials, including RNAs, DNAs, proteins, and lipids. EVs regulate a diverse range of pathophysio-
logical functions by activating receptors or transferring membrane proteins, signaling molecules, mRNAs, and miRNAs. These EVs can in-
teract with recipient cells by ligand-receptor interactions, fusion, and internalization via receptor-mediated endocytosis or macropinocytosis.
cell types and body fluids (13). Proteomic studies on EVs of 
various origins suggest a controlled protein-sorting mecha-
nism, rather than the random packaging of EV proteins, be-
cause EVs from different cell types contain common vesicular 
proteins. These common vesicular proteins are mainly in-
volved in vesicle structure, biogenesis, and trafficking: tetra-
spanins (CD9, CD63, and CD81), integrins, heat shock pro-
teins (Hsp60, Hsp70, and Hsp90), the endosomal sorting com-
plexes required for the transport complex (TSG101 and Alix), 
annexins, cytoskeleton proteins (actins, cofilin-1, ezrin/radi-
xin/moesin, profilin-1, and tubulins), metabolic enzymes, and 
ribosomal proteins (2) (Fig. 1). The proteins located in the plas-
ma membrane and cytoplasm are more commonly sorted into 
EVs compared with proteins in the nucleus and mitochondria 
(13, 14). Several studies have proposed mechanisms for vesic-
ular protein sorting (2, 14). Vesicular proteins are sorted by the 
endosomal-sorting complexes or by protein and lipid inter-
actions or by the internalization of cytosolic proteins (2). A re-
cent report has shown the co-sorting of cytoplasmic proteins 
with vesicular cargo proteins via protein-protein interactions in 
colorectal cancer cells (14). EVs also contain cell type-specific 
proteins. For example, melanoma-derived EVs contain the tu-
mor-associated antigen, MART1, while epithelial cell-derived 
EVs contain epithelial cell adhesion molecule, EpCAM (15, 
16). Additionally, vesicular EGFRVIII, detected in the plasma 
of glioblastoma patients, induces the activation of transforming 
signaling pathways and thus increases the anchorage-in-
dependent growth capacity (17). Moreover, docetaxel-resistant 
prostate cancer cells were found to release MDR-1, the drug 
transporter, via EVs and transfer drug resistance to non-re-
sistant prostate cancer cells (18).
Lipids
Extracellular vesicular lipids are known to play important roles 
in the rigidity, stability, function, and intracellular fusion and 
budding processes of EVs. Membrane lipids (sphingomyelin, 
phosphatidylcholine, phosphatidylethanolamine, phosphati-
dylserine, ganglioside GM3, and phosphatidylinositol), prosta-
glandins (E2, F2, J2, and D2), and lysobisphosphatidic acid are 
lipid components of EVs (19-22). Although the specific ratios 
of these lipids in EVs vary according to the originating cell, 
generally, EVs are enriched in sphingomyelin, cholesterol, 
GM3, and phosphatidylserine (21) (Fig. 1). Sphingomyelin and 
cholesterol allow the tight packing of lipid bilayers and in-
crease overall rigidity and stability (23, 24). GM3 also in-
creases the stability of EVs and prevents the recognition of EVs 
by blood components and uptake by the reticuloendothelial 
system (25). Moreover, conical-shaped phosphatidylserine 
helps to assemble the curved vesicular shape of EVs and facili-
tates the fusion and fission of the EVs (26). Sphingomyelin and 
prostaglandins also have functional roles other than maintain-
ing the structure of EVs. Sphingomyelin has a proangiogenic 
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Fig. 2. Multiple functions of extracellular vesicles in the tumor microenvironment. The tumor microenvironment consists of a diverse range of 
cells including cancer cells, endothelial cells, fibroblasts, macrophages/monocytes, and immune cells. This heterogeneous population of cells 
secretes EVs into the tumor microenvironment. These EVs make an environment favorable for tumor progression. Cancer cell-derived EVs pro-
mote angiogenesis by modulating endothelial cell proliferation, migration, and invasion directly. Also, these EVs stimulate angiogenesis by ac-
tivating macrophages to secrete proangiogenic factors and by promoting the induction of fibroblast differentiation into myofibroblasts. 
Moreover, cancer cell-derived EVs suppress immune responses by promoting the differentiation of monocytes into myeloid-derived suppressor 
cells and by inducing apoptosis of cytotoxic T lymphocytes.
character that can promote endothelial cell migration, tube for-
mation, and neovascularization (19). Moreover, EV-bound 
prostaglandins were found to activate signaling pathways in rat 
basophil leukemia cells (22). Furthermore, lipids modulating 
intracellular fusion and budding process, such as the lysobi-
sphosphatidic acid are involved in EV biogenesis (21).
Nucleic acids
EVs found in various cells and body fluids, such as plasma, sali-
va, and breast milk, contain mRNAs and miRNAs (2) (Fig. 1). 
Using microarray- and ‘next-generation’ sequencing-based sys-
tematic approaches, significant quantities of vesicular mRNA 
and miRNA have been reported. Horizontal transfer of vesicu-
lar mRNAs and miRNAs can lead to epigenetic reprogramming 
of recipient cells. Also, differences in the profiling of vesicular 
mRNAs and miRNAs in diseased conditions may potentially be 
useful as diagnostic tools (27, 28). Furthermore, in addition to 
mRNA and miRNA, EVs also contain rRNA, tRNA, mitochon-
drial DNA, and short DNA sequences of retrotransposons 
(29-31) (Fig. 1). Extracellular miRNA exist in various forms: en-
closed in EVs or high density lipoprotein particles, or asso-
ciated with Ago2 proteins (32). Because body fluids contain 
mixtures of RNases, miRNA should be enclosed in some vesic-
ular structure to escape RNase degradation. Recent studies 
have shown the presence of miRNA after treatment with 
RNases to the solution, suggesting the miRNA does exists with-
in EVs (27, 33). Although the sorting mechanism of miRNA into 
EVs remains unknown, several reports have shown that certain 
miRNAs are enriched in EVs, compared with the originating 
cells (27, 31). Extracellular vesicular miRNAs downregulate tar-
get mRNAs in recipient cells (31). Additionally, vesicular 
miRNAs can directly activate signaling molecules and receptors 
of the target cells. For example, exosomal miR-21 and miR-29a 
activate TLR7 and TLR8 receptors in immune cells, leading to 
tumor growth and metastasis (34, 35).
FUNCTIONS OF EXTRACELLULAR VESICLES
EVs regulate a diverse range of biological processes by trans-
ferring membrane proteins, signaling molecules, mRNAs, and 
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miRNAs, and activating receptors of recipient cells (6, 36) (Fig. 
1). The detailed mechanism(s) as to how these EVs interact 
with target cells remain(s) unknown. Some studies have sug-
gested that EVs can fuse with the plasma membrane of recipi-
ent cells and be internalized by the receptor-mediated endocy-
tosis or macropinocytosis (37-39). Local and long-distance in-
teractions of EVs with target cells control normal physiology 
and disease pathogenesis (40, 41).
　EVs exert pleiotropic effects in the maintenance of normal 
physiology, including tissue repair, stem cell maintenance, and 
blood coagulation (8, 41). EVs harboring membrane-bound 
morphogens, such as Wnt and Dll4, stimulate counterpart re-
ceptors and induce signal transduction involved in embryonic 
development and carcinogenesis (42, 43). Morphogen-asso-
ciated EVs directly activate cell surface receptors, rather than 
the forming a morphogen gradient in the tissue (44). EVs also 
have been implicated in stem cell maintenance and cell 
plasticity. Various studies have reported a pivotal role of stem 
cell-derived EVs in tissue regeneration after injury and in modu-
lating cellular phenotypes (45-47). EVs derived from embryonic 
stem cells modulate the pluripotency and the undifferentiated 
phenotype of stem cells (45). EVs derived from endothelial pro-
genitor cells also activate quiescent endothelial cells, switching 
on angiogenic processes by transferring mRNAs (46).
　In addition to the role of EVs during physiological processes, 
EVs participate in diverse pathological conditions, including 
cancer, infectious diseases, autoimmunity, and neurodegene-
ration (40, 41). In the brain, neurons, oligodendroglial cells, 
and microglia release EVs, which modulate various neuro-
biological functions (48-50). In addition to the synaptic neuro-
transmission, EVs containing neurotransmitter receptors partic-
ipate in the synaptic plasticity by enhancing glutamatergic ac-
tivity (49). Also, these EVs can regulate myelin formation, neu-
rite outgrowth, and neuronal survival (51, 52). In the patho-
genesis of neuronal disease, EVs are associated with several 
pathogenic proteins, such as prions, β-amyloid peptide, super-
oxide dismutase, and α-synuclein (53-55).
　EVs can also enhance or suppress autoimmunity and 
inflammation. In the synovial fluid of rheumatoid arthritis pa-
tients, EVs activate autologous fibroblast-like synoviocytes to 
release proinflammatory mediators and promote monocyte re-
cruitment to the inflammatory sites (56, 57). EVs from tumor 
cells induce immune response by transferring tumor antigens 
to dendritic cells (58). In contrast, tumor cell-derived EVs sup-
press immune responses by inducing apoptosis of activated cy-
totoxic T lymphocytes or promoting the differentiation of regu-
latory T lymphocytes (59). In addition to regulating the im-
mune responses, tumor-derived EVs play diverse roles in tu-
mor progression, including growth, invasion, metastasis, and 
angiogenesis (8) (Fig. 2). This review is focused on the roles of 
EVs in tumor progression.
Effects of cancer cell-derived EVs on endothelial cells
Several studies have reported the activation of in vitro and in 
vivo angiogenesis by EVs derived from cancer cells (19, 60) 
(Fig. 2). For example, a vesicular lipid component, sphingo-
myelin, triggers endothelial cell migration, tube formation, and 
neovascularization (19). Also, cell cycle-related mRNAs be-
longing to the M-phase are enriched in the transcripts of can-
cer cell-derived EVs and promote endothelial cell proliferation 
after internalization (60). In addition to the mRNA, proteins are 
also transferred to recipient cells. For example, activated EGFR 
in EVs is transferred to EGFR-negative endothelial cells and, in 
turn, triggers endothelial cell activation via the MAPK and AKT 
signal transduction pathways (61). EVs from glioblastomas also 
contain angiogenic proteins, such as angiogenin, FGF1, IL-6, 
IL-8, TIMP-1, TIMP-2, and VEGF (28, 62). 
Effects of cancer cell-derived EVs on macrophages
Macrophages play an important role in vessel formation during 
wound repair, inflammation, and tumor growth (63). A sig-
nificant reduction in neovascularization and tumor growth was 
observed in monocyte-depleted mice and in nude mice (64, 
65). Also, macrophages isolated from tumors have angiogenic 
activities in endothelial cells in vitro and in vivo (66). In tu-
mors, potential stimulators of macrophages are low oxygen 
tensions, wound-like concentrations of lactate, pyruvate, or hy-
drogen ions, or cytokines such as IFN-γ, granulocyte macro-
phage colony-stimulating factor, platelet-activating factor, or 
monocyte chemotactic protein (63). Macrophages activated by 
such tumor stimuli release secretory products and are able to 
promote all phases of the angiogenic process: destruction of 
the local extracellular matrix, endothelial cell migration, pro-
liferation, and differentiation (67). Macrophage-derived factors 
include proteases, growth factors, and monokines, such as col-
lagenases, tissue plasminogen activator, urokinase-type plasmi-
nogen activator, FGF2, VEGF, IL-8, IL-6, and TNF-α (63). 
These factors promote angiogenesis, but act in an indirect 
manner through attracting or activating other angiogenic cells. 
In tumors, endothelial cells are activated and produce endo-
thelial adhesion molecules and cytokines that stimulate the mi-
gration and activation of monocytes and macrophages (68).
　Cancer cell-derived EVs modulate the tumor microenviron-
ment, which is favorable for tumor growth and invasion, by 
promoting tumor angiogenesis and immune suppression (19, 
69). Recently, several groups have investigated the im-
munosuppressive roles of cancer cell-derived EVs (69-71) (Fig. 
2). Melanoma- or colorectal cancer cell-derived EVs promoted 
the differentiation of monocytes into myeloid-derived sup-
pressor cells (MDSCs) and inhibited T cell proliferation and ef-
fector functions and thus suppressed the antitumor immune re-
sponse (69). Furthermore, EVs derived from B16 melanoma 
blocked their differentiation into mature dendritic cells by acti-
vating the accumulation of CD11b+Gr-1+ MDSCs (71). These 
CD11b+Gr-1+ cells release cytokines and chemokines, such as 
TNF-α, IL-6, and CCL2, and promote lung metastasis (71). 
Additionally, conditioned medium from tumor cells can in-
duce the migration of monocytes and mediate M2 polarization 
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of macrophages (69). When human blood monocytes are cul-
tured with conditioned media from different cancer cells, sev-
eral genes related to M2-polarized macrophages were upregu-
lated (70). The results of these studies suggest that cancer 
cell-derived EVs activate tumor-infiltrating macrophages and 
MDSCs to secret angiogenic factors, leading to tumor growth, 
metastasis, and angiogenesis (Fig. 2).
Effects of cancer cell-derived EVs on fibroblasts
Cancer-associated fibroblasts are abundant in the tumor stroma 
and they stimulate inflammation and angiogenesis (72, 73). 
Stromal myofibroblasts are characterized by a contractile cell 
type and the expression of smooth muscle actin (α-SMA) (74). 
Myofibroblasts are important in solid cancers with an altered 
stroma, promoting angiogenesis and local extracellular matrix 
remodeling (75). Stromal fibroblasts participate in tumor angio-
genesis by secreting proangiogenic growth factors (e.g. VEGF, 
FGF2, TGF-β, PDGF, HGF, and IL-8) and matrix remodeling 
proteins (e.g. MMP-1, MMP-2, MMP-3, MMP-7, MMP-11, and 
MTMMP1) (72, 73). The recruited myofibroblasts act as the 
main source of VEGF and compensate for the loss of VEGF in 
the tumor cells (76). Proinflammatory cytokines and chemo-
kines released by myofibroblasts recruit immune cells, includ-
ing macrophages, neutrophils, and mast cells to the local site 
(75, 77). Although myofibroblasts are important components of 
the tumor stroma, the interactions between cancer cells and 
stromal fibroblasts have not been investigated in detail. A recent 
study revealed that cancer cell-derived EVs promote the in-
duction of fibroblast differentiation to myofibroblasts (78) (Fig. 
2). Prostate cancer cell-derived EVs contain TGF-β protein at the 
surface, associated with the type-3 TGF-β receptor, betaglycan 
(78). In EVs, TGF-β exists in a biologically active form and elic-
its SMAD-dependent signaling, elevating α-SMA expression, in-
ducing a myofibroblastic phenotype (78). Moreover, fibro-
blast-derived EVs were found to facilitate breast cancer cell pro-
trusion, motility, and metastasis through Wnt-planar cell polarity 
signaling (79). The Wnt signaling pathway is triggered by the 
tetraspanin CD81 and Wnt11 loaded inside the EVs (79).
CLINICAL APPLICATIONS OF EXTRACELLULAR VESICLES
EVs are potential biomarkers for the detection, diagnosis, and 
prognosis of patients, particularly in cancer. Several studies 
have revealed that EVs can be detected in tumor tissue and 
body fluids, such as malignant effusions, serum, and urine of 
cancer patients (80, 81). In cancer patients, the quantity of EVs 
is elevated and the composition of vesicular proteins, mRNAs, 
and miRNAs varies significantly by disease state (40). Recent 
progress in high-throughput tools has provided valuable in-
formation on disease-specific vesicular proteins, mRNAs, and 
miRNAs. EVs can be detected using non-invasive methods in 
the body fluids of cancer patients (82). Furthermore, among 
the vesicular biomarkers, proteins and RNAs of luminal cargos 
are protected from hydrolytic and enzymatic degradation in 
the extracellular environment (83). Thus, EVs are a good 
source of proteins and RNAs biomarkers of tumor progression.
　In addition to the diagnostic potential of EVs in tumor biol-
ogy, recent studies have drawn attention to the potential of EVs 
as therapeutic agents by inhibiting EVs biogenesis, release, cell 
uptake, or specific vesicular components (8, 82). Because the 
level of circulating EVs increases in various body fluids of can-
cer patients, the reduction of circulating EVs may inhibit tu-
morigenesis (80, 81). The production of EVs can be inhibited 
by blocking the target of microtubule assembly and stability, 
endosomal sorting pathways, or proton pumps (84-86). For ex-
ample, ceramide, tetraspanin, and syndecan proteoglycans are 
crucial for the formation of EVs (87-89). Small-molecule in-
hibitors of sphingomyelinase or amiloride attenuate endosomal 
sorting and endocytic vesicle recycling and vesicle production, 
and, consequently, lead to a reduction in tumor growth (87, 
88). Because the release of EVs depends on the small GTPase 
RAB27A, RNA interference treatment for RAB27A can also re-
duce tumor growth and metastasis (85). EVs derived from tu-
mors harbor several functional vesicular proteins, mRNAs, and 
miRNAs involved in cancer progression. By blocking or deplet-
ing the functional cargos with small-molecule inhibitors and 
RNA interference, EV-mediated tumorigenesis can be attenu-
ated (8, 82). Furthermore, EVs can be used as delivery systems 
for drugs, proteins, miRNA/siRNA, and other molecules (82, 
90). By using intrinsic EVs or bioengineered exosome-mim-
etics, therapeutic agents can be delivered to diverse target cells, 
especially endothelial cells, and further lead to the attenuation 
of tumor growth and metastasis (90-92).
CONCLUDING REMARKS
In recent decades, EVs (exosomes and microvesicles) were re-
garded as just cellular debris (93). However, more recent find-
ings on cargo sorting, biogenesis, components, and pathophy-
siological roles of the EVs have suggested that EVs are, in fact, 
complex extracellular organelles mediating intercellular com-
munication (‘communicasomes’) (1, 2, 14). Indeed, EVs harbor 
complex vesicular components regulating a diverse range of 
physiological and pathological functions (2). In this review, we 
focused on the components, their functions, and the ther-
apeutic and diagnostic potential of EVs derived from mamma-
lian cells. As the release of EVs is an evolutionarily conserved 
process occurring from archaea, Gram-negative and Gram-pos-
itive bacteria, to eukaryotic cells, the role of EVs may be ex-
panded as communicasomes in interspecies and even inter-
kingdom communications (3, 4). Thus, explaining the complex-
ity of EVs in relation to intercellular communications could pro-
vide hints to as-yet unknown mechanisms to various pathophy-
siological conditions and apply in the development of novel di-
agnostic and therapeutic tools for understanding, detecting, and 
treating diseases.
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